Jane Street
INMB icon

Jane Street’s INmune Bio INMB Stock Holding History

Jane Street’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,600
Closed -$206K – 10429
2021
Q3 		$206K Buy
+10,600
New +$205K ﹤0.01% 8794

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Jane Street's INMB Position: Q2 2026 in Review

Jane Street increased its INmune Bio (INMB) stake by 163% in Q2 2026, buying an estimated $115K and bringing the position to 134,232 shares worth $219K. The position accounts for ﹤0.01% of the portfolio, ranked #9927.

Jane Street first reported a position in INMB in Q1 2021 and has held it in 10 quarters since. The position peaked at $869K in Q1 2024. 82 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Jane Street held 134,232 shares of INmune Bio worth $219K as of Q2 2026.
  • Jane Street bought 83,288 INmune Bio shares in Q2 2026, an estimated $115K.
  • INmune Bio made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #9927 holding.
  • Jane Street first reported a position in INmune Bio in Q1 2021 and has held it in 10 quarters since.
  • Jane Street's INmune Bio position peaked at $869K in Q1 2024.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.